Noribogaine generalization to the ibogaine Stimulus: Correlation with noribogaine concentration in rat brain

Neuropsychopharmacology

Volumn 21, Issue 1, 1999, Pages 119-126

  Zubaran, C ^a,b   Shoaib, M ^a   Stolerman, I P ^a   Pablo, J ^c   Mash, D C ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

opioids; Dizocilpine; Drug discrimination; Ibogaine; Noribogaine; Rats

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; DIZOCILPINE; IBOGAINE; KAPPA OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORIBOGAINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISCRIMINATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANIMALS; BRAIN; DISCRIMINATION (PSYCHOLOGY); DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GENERALIZATION (PSYCHOLOGY); HALLUCINOGENS; IBOGAINE; MALE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, KAPPA;

EID: 0033051236     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00003-2     Document Type: Article

References (35)

1. Bhargava H.N., Cao Y.-J. Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice. Brain Res. 771:1997;343-346.
2. Cappendijk S.L.T., Dzoljic M.R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol. 241:1993;261-265.
3. Chamberlain S.S., Stolerman I.P. Dissecting the cyclazocine stimulus in rats. J Psychopharmac. 11(Suppl):1997;A13.
4. Deecher D.C., Teitler M., Soderlund D.M., Bornmann W.G., Kuehne M.E., Glick S.D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 571:1992;242-247.
5. Glick S.D., Pearl S.M., Cai J., Maisonneuve I.M. Ibogaine-like effects of noribogaine in rats. Brain Res. 713:1996;294-297. a.
6. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., Molinari H.H. 18-methoxycoronaridine, a non-toxic iboga alkaloid congener. Effect on morphine and cocaine self-administration and on mesolimbic dopamine release in rats Brain Res. 719:1996;29-35. b.
7. Hearn W.L., Pablo J., Hime G.W., Mash D.C. Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry. J Anal Toxicol. 19:1995;427-434.
8. Helsley S., Rabin R.A., Winter J.C. The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus. Life Sci. 60:1997;147-153.
9. 2A component of the ibogaine-induced discriminative stimulus. Pharmacol Biochem Behav. 59:1998;419-425. a.
10. Helsley S., Filipink R.A., Bowen W.D., Rabin R.A., Winter J.C. The effects of sigma, PCP, and opiate receptors ligands in rats trained with ibogaine as a discriminative stimulus. Pharmacol Biochem Behav. 59:1998;495-503. b.
11. Hough L.B., Pearl S.M., Glick S.D. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci. 58:1996;119-122.
12. Jones H.E., Li H., Balster R.L. Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav. 59:1998;413-418.
13. Ley F.R., Jeffcoat A.R., Thomas B.F. Determination of ibogaine in plasma by gas chromatography-chemical ionization mass spectrometry. J Chromatogr A. 723:1996;101-109.
14. Lotsof HS (1985): Rapid method for interrupting the narcotic addiction syndrome. US Patent 4,499,096.
15. Lotsof HS (1992): Rapid method for interrupting or attenuating poly-drug dependency syndromes. US Patent 5,152,994.
16. Maisonneuve I.M., Keller R.W. Jr., Glick S.D. Interactions between ibogaine, a potential anti-addictive agent, and morphine. An in vivo microdialysis study Eur J Pharmacol. 199:1991;35-42.
17. Maisonneuve I.M., Visker K.E., Mann G.L., Bandarage U.K., Kuehne M.E., Glick S.D. Time-dependent interactions between iboga agents and cocaine. Eur J Pharmacol. 336:1997;123-126.
18. Mash D.C., Staley J.K., Baumann M.H., Rothman R.B., Hearn W.L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 57:1995;45-50. a.
19. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci Lett. 192:1995;53-56. b.
20. Palumbo P.A., Winter J.C. Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD. Pharmacol Biochem Behav. 43:1992;1221-1226.
21. Pearl S., Herrick-Davis K., Teitler M., Glick S.D. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res. 675:1995;342-344.
22. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology. 114:1994;672-674.
23. Popik P., Layer R.T., Fossom L.H., Benveniste M., Geter-Douglass B., Witkin J.M., Skolnick P. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J Pharmacol Exp Ther. 275:1995;753-760.
24. Pratt J.A., Stolerman I.P., Garcha H.S., Giardini V., Feyerabend C. Discriminative stimulus properties of nicotine. Further evidence for mediation at a cholinergic receptor Psychopharmacology. 81:1983;54-60.
25. Sanger D.J., Zivkovic B. The discriminative stimulus effects of MK-801. Generalisation to other N-methyl-D-aspartate receptor antagonists J Psychopharmacol. 3:1989;198-204.
26. Scallet A.C., Ye X., Ali S.F. NOS and fos in rat and mouse brain regions. Possible relation to ibogaine-induced Purkinje cell loss. Ann N Y Acad Sci. 801:1996;227-238.
27. Schechter M.D. Serotonergic mediation of fenfluramine discriminative stimuli in Fawn-Hooded rats. Life Sci. 60:1997;83-90.
28. Schechter M.D., Gordon T.L. Comparison of the behavioural effects of ibogaine from three sources. Mediation of discriminative activity Eur J Pharmacol. 249:1993;79-84.
29. Sheppard S.G. A preliminary investigation of ibogaine. Case reports and recommendations for further study J Subst Abuse Treat. 11:1994;379-385.
30. Staley J.K., Ouyang Q., Pablo J., Hearn W.L., Flynn D.D., Rothman R.B., Rice K.C., Mash D.C. Pharmacological screen for activities of 12-hydroxyibogamine. A primary metabolite of the indole alkaloid ibogaine Psychopharmacology. 127:1996;10-18.
31. Stolerman I.P., Garcha H.S., Pratt J.A., Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology. 84:1984;413-419.
32. Sweetnam P.M., Lancaster J., Snowman A., Collins J.L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology. 118:1995;369-376.
33. Winer B.J. Statistical Principles in Experimental Design. 1970;McGraw-Hill, New York.
34. Witkin J.M., Brave S., French D., Geter-Douglass B. Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther. 275:1995;1267-1273.
35. Zetler G., Singbartl G., Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology. 7:1972;237-248.